Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.44 |
| ▸ | USP7 | Q93009 | 2/20 | 0.41 |
| ▸ | FYN | P06241 | 2/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16455947 | 0.81 | MAP4K4 (0.47) | LRRK2DGAT1MAP4K4USP7FYN | |
| SCHEMBL16455942 | 0.72 | DYRK1A (0.46) | LRRK2DGAT1MAP4K4USP7TNKS | |
| SCHEMBL16455969 | 0.72 | DGAT1 (0.45) | LRRK2DGAT1MAP4K4USP7FYN | |
| SCHEMBL16758538 | 0.67 | LRRK2 (0.52) | LRRK2DGAT1MAP4K4 | |
| SCHEMBL16456329 | 0.67 | TNKS (0.58) | LRRK2MAP4K4USP7FYNTNKS | |
| SCHEMBL25094279 | 0.66 | KIF11 (0.55) | DGAT1 | |
| SCHEMBL12548476 | 0.65 | RAB9A (0.55) | DGAT1MAP4K4 | |
| SCHEMBL28175377 | 0.65 | DGAT1 (0.51) | DGAT1KCNH2 | |
| SCHEMBL16455935 | 0.64 | KIF11 (0.45) | DGAT1MAP4K4 | |
| SCHEMBL13483886 | 0.64 | PIK3CD (0.52) | DGAT1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340549-B2 | Oxazolidinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | TNKS1BP1, TNKS, TBKBP1 | LRRK2 2305/4885DGAT1 3659/4885MAP4K4 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.